Patent Expands Niagen’s Leadership in NAD+ Delivery, Supporting Faster and Safer Treatments
Why is the race for intellectual property in the NAD+ market heating up? Niagen Bioscience, Inc. a global leader in NAD+ science and healthy aging, has announced the issuance of U.S. Patent No. 12,558,367, which significantly broadens its intellectual property (IP) portfolio. This new patent covers the methods of using nicotinamide riboside (NR) and its derivatives in intravenous (IV) and injectable formulations, reinforcing Niagen’s position in the rapidly growing NAD+ market.
Rob Fried, CEO of Niagen Bioscience, emphasized the strategic importance of this patent: “This patent expands our intellectual property for our patented NR ingredient, Niagen®, into IV and injectable delivery formats. With expected protection through 2044, it supports Niagen’s exclusivity in delivering a superior IV and injectable product with significantly faster delivery and improved comfort for patients across our expanding U.S. clinic footprint.” This announcement not only solidifies Niagen’s market leadership but also sets the stage for further commercial expansion and innovation.
Key Insights at a Glance
- Patent Protection: U.S. Patent No. 12,558,367 covers methods of using NR in IV and injectable formulations.
- Faster Delivery: Niagen’s IV formulation supports faster infusions and higher NAD+ levels without severe side effects.
- Commercial Expansion: The patent supports Niagen’s growing U.S. clinic footprint and additional commercial pathways.
- Robust IP Portfolio: Niagen owns and licenses over 100 patents, reinforcing its leadership in NAD+ science.
Why NAD+ Delivery Methods Matter in the Health and Wellness Industry
The demand for NAD+ treatments is surging, driven by the growing interest in healthy aging and cellular health. Traditional NAD+ IV treatments, while effective, often come with significant side effects and longer infusion times. Niagen Bioscience’s new patent addresses these challenges by providing a more efficient and comfortable delivery method. Just as a well-designed irrigation system ensures water reaches every part of a garden efficiently, Niagen’s IV and injectable formulations ensure that NAD+ is delivered to cells quickly and effectively, enhancing patient comfort and treatment outcomes.
The Regulatory Clock Is Already Running for NAD+ Providers
The newly issued patent is a critical step in securing Niagen Bioscience’s market position. Like a sprinter taking their mark, the company is poised to capitalize on the growing demand for NAD+ treatments. The patent’s broad claims, covering aqueous formulations, multiple administration routes, and combination use with other NAD+ precursors, provide a robust defense against potential infringers. This strategic move not only protects Niagen’s innovations but also opens the door for new commercial partnerships and pathways. With the patent expected to provide protection through 2044, Niagen Bioscience is well-positioned to lead the NAD+ market for decades to come.
Niagen Bioscience Expands Its IV and Injectable Product Portfolio
Niagen Bioscience has developed a next-generation intravenous formulation of pharmaceutical-grade Niagen, designed to support healthy aging and longevity at the cellular level. This new formulation, part of the Niagen Plus product portfolio, offers several key advantages over traditional NAD+ IV treatments. It supports faster infusions, elevates NAD+ levels higher, and minimizes the severe side effects often associated with NAD+ IV. As Rob Fried noted, “This patent supports Niagen’s exclusivity in delivering a superior IV and injectable product.” The company’s commitment to innovation and patient comfort is evident in its ongoing evaluation and development of next-generation NAD+ precursors.
Future Outlook
The landscape of NAD+ treatments is evolving rapidly, and Niagen Bioscience is at the forefront of this transformation. Just as a lighthouse guides ships through treacherous waters, Niagen’s robust IP portfolio and innovative formulations will guide the industry toward safer and more effective NAD+ delivery methods. With over 1,200 healthcare, wellness, and longevity clinics across the U.S. offering Niagen IV, the company is well-prepared to meet the growing demand. The newly issued patent, expected to provide protection through 2044, ensures that Niagen Bioscience will continue to lead the way in NAD+ science and healthy aging.
Conclusion
This new patent is a significant milestone for Niagen Bioscience, solidifying its leadership in the NAD+ market and paving the way for further innovation. For healthcare providers and patients, this means faster, safer, and more effective NAD+ treatments. How is your clinic or practice preparing to integrate these advanced NAD+ formulations? Join the conversation in the comments below.
About Niagen Bioscience:
Niagen Bioscience, Inc. is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.
The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.
Source link: https://www.businesswire.com/
